Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12

Benzinga Newsdesk www.benzinga.com Negative 72.5%

Neg 72.5% Neu 0% Pos 0%

Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.